On October 29, 2020 Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, reported that it has rescheduled today’s conference call due to technical issues with a third-party provider (Press release, Protalix, OCT 29, 2020, View Source [SID1234569437]). The rescheduled call to discuss the financial results and provide a general business update will take place on Friday, October 30, 2020 at 8:30 a.m. Eastern Daylight Time (EDT). The Company reported financial results for the third quarter ended September 30, 2020, and provided a business update on recent corporate and clinical developments in a press release issued earlier today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rescheduled Conference Call and Webcast Information:

The conference call will be webcast live from the Company’s website and will be available via the following links:

Webcast Details:

Company Link: View Source
Webcast Link: View Source
Conference ID: 13712792

Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.

The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company’s website, at the above link.